Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Non-Current Assets: 2016-2024

Historic Non-Current Assets for Collegium Pharmaceutical (COLL) over the last 9 years, with Dec 2024 value amounting to $1.2 billion.

  • Collegium Pharmaceutical's Non-Current Assets fell 16.61% to $993.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $993.5 million, marking a year-over-year decrease of 16.61%. This contributed to the annual value of $1.2 billion for FY2024, which is 95.03% up from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Non-Current Assets of $1.2 billion as of FY2024, which was up 95.03% from $605.7 million recorded in FY2023.
  • Collegium Pharmaceutical's Non-Current Assets' 5-year high stood at $1.2 billion during FY2024, with a 5-year trough of $366.0 million in FY2020.
  • Moreover, its 3-year median value for Non-Current Assets was $754.1 million (2022), whereas its average is $847.1 million.
  • As far as peak fluctuations go, Collegium Pharmaceutical's Non-Current Assets skyrocketed by 623.48% in 2020, and later decreased by 19.68% in 2023.
  • Yearly analysis of 5 years shows Collegium Pharmaceutical's Non-Current Assets stood at $366.0 million in 2020, then grew by 2.89% to $376.5 million in 2021, then soared by 100.29% to $754.1 million in 2022, then declined by 19.68% to $605.7 million in 2023, then spiked by 95.03% to $1.2 billion in 2024.